Breaking News Instant updates and real-time market news.

ALNY

Alnylam

$70.30

1.73 (2.52%)

, MDCO

The Medicines Co.

$38.51

0.32 (0.84%)

07:37
10/06/16
10/06
07:37
10/06/16
07:37

Alnylam news not a negative read through on other RNAi drugs, says RBC Capital

After Alnylam (ALNY) announced that it was discontinuing one of its Phase III RNAi drugs due to poor clinical outcomes, RBC Capital analyst Michael Yee does not thinks that the news indicates problems with all RNAi drugs. Rather, he thinks that RNAi was not the proper treatment for the disease that Alnylam was targeting. Other companies with RNAi treatments include The Medicines Company (MDCO0, Ionis Pharmaceuticals (IONS), Arrowhead (ARWR), and Arbutus Biopharma (ABUS).

ALNY

Alnylam

$70.30

1.73 (2.52%)

MDCO

The Medicines Co.

$38.51

0.32 (0.84%)

IONS

Ionis Pharmaceuticals

$36.38

0.72 (2.02%)

ARWR

Arrowhead

$7.52

0.23 (3.16%)

ABUS

Arbutus Biopharma

$3.50

0.125 (3.71%)

  • 07

    Oct

  • 14

    Oct

  • 06

    Nov

ALNY Alnylam
$70.30

1.73 (2.52%)

10/06/16
LEER
10/06/16
DOWNGRADE
Target $40
LEER
Market Perform
Alnylam downgraded to Market Perform from Outperform at Leerink
Leerink analyst Michael Schmidt downgraded Alnylam Pharmaceuticals to Market Perform after the company discontinued development of revusiran. To reflect an increased level of uncertainty around the company's pipeline, the analyst cut his price target for the shares to $40 from $107. JPMorgan and Barclays also downgraded Alnylam this morning while Piper Jaffray recommends buying the stock on weakness.
10/06/16
JEFF
10/06/16
NO CHANGE
Target $43
JEFF
Buy
Alnylam setback has no read-through to Medicines Co., says Jefferies
Jefferies analyst Biren Amin believes Alnylam Pharmaceuticals' (ALNY) decision to stop revusiran due to lack of a treatment benefit has no read-through to The Medicines Co.'s (MDCO) PCSK9 program. Amin keeps a Buy rating on Medicines Co. with a $43 price target.
10/06/16
PIPR
10/06/16
NO CHANGE
Target $46
PIPR
Overweight
Piper thinks Alnylam failure is positive for Ionis
Piper Jaffay analyst Joshua Schimmer thinks Alnylam Pharmaceuticals' (ALNY) "abrupt halt" of revusiran for TTR cardiomyopathy is likely a positive for Ionis Pharmaceuticals' (IONS) transthyretin program. The move "knocks out a competitive drug" while Ionis and GlaxoSmithKline (GSK) remain on their previously indicated timeline, Schimmer tells investors in a research note. The analyst at this point believes Alnylam's setback will be limited to revusiran and not read-through to other Gal-Nac programs or other TTR cardiomyopathy or polyneuropathy programs. He keeps an Overweight rating on Ionis with a $46 price target,
10/06/16
JEFF
10/06/16
NO CHANGE
Target $58
JEFF
Buy
Alnylam price target lowered to $58 from $86 at Jefferies
Jefferies analyst Gena Wang lowered her price target for Alnylam Pharmaceuticals to $58 from $86 following the termination of revusiran Phase 3 due to mortality imbalance. The analyst believes the setback, while "major," is likely to be program specific and not impact the company's other trials. She keeps a Buy rating on Alnylam.
MDCO The Medicines Co.
$38.51

0.32 (0.84%)

09/09/16
LEER
09/09/16
NO CHANGE
LEER
Leerink updates therapeutics best ideas for 2016
In a note to investors this morning, Leerink has updated its best ideas for 2016 from the firm's five therapeutics analysts. The list includes Alexion (ALXN), Dermira (DERM), Intra-Cellular (ITCI), Sanofi (SNY), Allergan (AGN), Alnylam (ALNY), Innate Pharma (IPHYF), The Medicines Co. (MDCO), and Ophthotech (OPHT).
07/11/16
JEFF
07/11/16
NO CHANGE
Target $43
JEFF
Buy
Jefferies views The Medicines Co. ruling as positive surprise
Jefferies analyst Biren Amin views today's Court of Appeals ruling as a "positive surprise" for The Medicines Company. The ruling "breathes potential life" into the company's Angiomax patents, Amin tells investors in a research note. He expects Hospira to file an appeal within 90 days. The analyst has a Buy rating on The Medicines Co. with a $43 price target.
08/02/16
EVER
08/02/16
NO CHANGE
EVER
Buy
Pfizer shelves oral PCSK9, a Medicines Co. competitor, says Evercore ISI
Evercore ISI analyst Umer Raffat said Pfizer (PFE) management does not thin the profile for oral PCSK9 will be competitive with the strong efficacy of antibodies and have moved other interesting products forward. Raffat said some Medicines Co. (MDCO) investors had worried that a potential oral PCSk9 from Pfizer could greatly reduce enthusiasm for an every-6-month PCSk9 from MDCO. The analyst said the next catalyst for The Medicines Co. is A1 Milano readout this month. Raffat rates The Medicines Co. a Buy with a $52 price target.
IONS Ionis Pharmaceuticals
$36.38

0.72 (2.02%)

09/28/16
JANY
09/28/16
INITIATION
Target $47
JANY
Buy
Ionis Pharmaceuticals initiated with a Buy at Janney Capital
Janney Capital analyst Roy Buchanan initiated Ionis Pharmaceuticals with a Buy and a $47 fair value estimate. Buchanan believes the late stage pipeline, including wholly-owned volanesorsen, and the base technology can add meaningful value to Ionis. 1H 2017 is particularly rich with 3 phase 3 readouts, with potential for another early, interim look at SMA.
10/06/16
BMOC
10/06/16
UPGRADE
BMOC
Outperform
Ionis Pharmaceuticals upgraded to Outperform from Market Perform at BMO Capital
10/04/16
RBCM
10/04/16
NO CHANGE
Target $375
RBCM
Outperform
Biogen could rise $20 or more per share on SMA success, says RBC Capital
RBC Capital analyst Michael Yee expects the first presentation of data from Biogen's (BIIB) Phase III ENDEAR trial studying nusinersen, an investigational treatment for spinal muscular atrophy, or SMA, this week, potentially during the late breaker session at the WMS Congress on October 8. Biogen and partner Ionis Pharmaceuticals (IONS) already announced in August that the study in Type I infants hit the interim analysis and stopped early for positive data. The much larger opportunity in older children has data expected to read out in Spring 2017, noted Yee, who thinks Biogen can have upside from $10 to over $20 per share based on its SMA opportunity. Yee keeps an Outperform rating and $375 price target on Biogen shares.
ARWR Arrowhead
$7.52

0.23 (3.16%)

08/18/16
08/18/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Barnes & Noble (BKS) initiated with a Neutral at Sidoti. 2. Digital Ally (DGLY) initiated with a Buy at Maxim. 3. Korn/Ferry (KFY) initiated with a Hold at Deutsche Bank. 4. Phillips 66 Partners (PSXP) initiated with a Buy at Stifel. 5. Arrowhead (ARWR) initiated with a Buy at Cantor. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/19/16
WBLR
08/19/16
INITIATION
Target $9
WBLR
Outperform
Arrowhead initiated with an Outperform at William Blair
William Blair analyst Y. Katherine Xu started Arrowhead Pharmaceuticals with an Outperform rating and $9 price target.
08/17/16
CANT
08/17/16
INITIATION
Target $15
CANT
Buy
Arrowhead initiated with a Buy at Cantor
Target $15.
09/29/16
PIPR
09/29/16
NO CHANGE
Target $10
PIPR
Overweight
Arrowhead price target raised to $10 from $8 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Arrowhead Pharmaceuticals (ARWR) to $10 after the company licensed two preclinical cardiovascular RNAi drugs with Amgen (AMGN). Amgen is the "ideal partner" and Arrowhead's balance sheet is now "meaningfully" strengthened, Tenthoff tells investors in a research note. He reiterates an Overweight rating on Arrowhead.
ABUS Arbutus Biopharma
$3.50

0.125 (3.71%)

08/19/16
08/19/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Aratana Therapeutics (PETX) assumed with a Buy at Jefferies. 2. Arbutus Biopharma (ABUS) initiated with an Outperform at William Blair. 3. Acceleron (XLRN) initiated with a Buy at BTIG. 4. Agios Pharmaceuticals (AGIO) initiated with a Neutral at BTIG. 5. Suncor (SU) reinstated with a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/19/16
WBLR
08/19/16
INITIATION
Target $7
WBLR
Outperform
Arbutus Biopharma initiated with an Outperform at William Blair
William Blair analyst Y. Katherine Xu started Arbutus Biopharma with an Outperform rating and $7 price target.
08/05/16
LEER
08/05/16
DOWNGRADE
LEER
Market Perform
Arbutus Biopharma downgraded to Market Perform from Outperform at Leerink
07/08/16
CHDN
07/08/16
DOWNGRADE
CHDN
Sell
Arbutus Biopharma downgraded to Sell from Neutral at Chardan

TODAY'S FREE FLY STORIES

UPLD

Upland Software

$17.07

0.16 (0.95%)

09:19
04/24/17
04/24
09:19
04/24/17
09:19
Earnings
Upland Software raises FY17 revenue view to $87.0M-$91.0M, consensus $84.18M »

Upland announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

09:19
04/24/17
04/24
09:19
04/24/17
09:19
Hot Stocks
Breaking Hot Stocks news story on Halliburton »

Halliburton sees Q2 North…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 01

    May

  • 01

    May

  • 17

    May

SPX

S&P 500

, VIX

Volatility Index S&P 500 Options

$11.48

-3.15 (-21.53%)

09:19
04/24/17
04/24
09:19
04/24/17
09:19
Options
Overnight activity included 387 trades in SPX and 61 trades in VIX »

387 trades were executed…

SPX

S&P 500

VIX

Volatility Index S&P 500 Options

$11.48

-3.15 (-21.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHKP

Check Point

$103.41

0.77 (0.75%)

09:18
04/24/17
04/24
09:18
04/24/17
09:18
Recommendations
Check Point analyst commentary  »

Check Point price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

  • 12

    Jun

TWTR

Twitter

09:17
04/24/17
04/24
09:17
04/24/17
09:17
Recommendations
Twitter analyst commentary  »

Twitter can beat Q1 but…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UPLD

Upland Software

$17.07

0.16 (0.95%)

09:17
04/24/17
04/24
09:17
04/24/17
09:17
Hot Stocks
Upland Software acquires RightAnswers »

Upland Software announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAS

Hasbro

$96.03

0.02 (0.02%)

09:16
04/24/17
04/24
09:16
04/24/17
09:16
Hot Stocks
Hasbro says has 'right brands, right team' to drive blueprint »

Regarding any potential…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 18

    May

  • 31

    May

ADI

Analog Devices

$77.63

-1.03 (-1.31%)

, LLTC

Linear Technology

09:15
04/24/17
04/24
09:15
04/24/17
09:15
Upgrade
Analog Devices, Linear Technology rating change  »

Analog Devices upgraded…

ADI

Analog Devices

$77.63

-1.03 (-1.31%)

LLTC

Linear Technology

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

HAL

Halliburton

09:12
04/24/17
04/24
09:12
04/24/17
09:12
Hot Stocks
Halliburton says momentum building in North America »

Says believes a bottom…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 01

    May

  • 01

    May

  • 17

    May

GM

General Motors

09:12
04/24/17
04/24
09:12
04/24/17
09:12
Recommendations
General Motors analyst commentary  »

General Motors Q1 likely…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

HAL

Halliburton

09:11
04/24/17
04/24
09:11
04/24/17
09:11
Hot Stocks
Halliburton says seeing customers deferring new projects »

Says customers more…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 01

    May

  • 01

    May

  • 17

    May

ALKS

Alkermes

$56.57

-0.16 (-0.28%)

, ACOR

Acorda Therapeutics

$15.85

-0.1 (-0.63%)

09:10
04/24/17
04/24
09:10
04/24/17
09:10
Recommendations
Alkermes, Acorda Therapeutics analyst commentary  »

Alkermes 2019 earnings…

ALKS

Alkermes

$56.57

-0.16 (-0.28%)

ACOR

Acorda Therapeutics

$15.85

-0.1 (-0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 27

    Apr

  • 27

    Apr

  • 03

    May

  • 06

    Jun

  • 08

    Jun

WTKWY

Wolters Kluwer

$41.04

-0.83 (-1.98%)

09:09
04/24/17
04/24
09:09
04/24/17
09:09
Hot Stocks
Wolters Kluwer to explore strategic alternatives for Corsearch »

Wolters Kluwer announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

$47.06

-0.63 (-1.32%)

09:09
04/24/17
04/24
09:09
04/24/17
09:09
Hot Stocks
Halliburton says not chasing market share at cost of pricing »

Says seeing sufficient…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 01

    May

  • 01

    May

  • 17

    May

GOGO

Gogo

$12.34

0.49 (4.14%)

09:09
04/24/17
04/24
09:09
04/24/17
09:09
Hot Stocks
Gogo signs new capacity deal with SES »

SES announced that Gogo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

GLD

SPDR Gold Trust

$122.31

0.35 (0.29%)

, SLV

iShares Silver Trust

$17.02

-0.04 (-0.23%)

09:08
04/24/17
04/24
09:08
04/24/17
09:08
Technical Analysis
Indexes and Sectors breakout above pivot highs and lows »

The major index ETFs,…

GLD

SPDR Gold Trust

$122.31

0.35 (0.29%)

SLV

iShares Silver Trust

$17.02

-0.04 (-0.23%)

TLT

iShares 20+ Year Treasury Bond Fund

XLF

Financial Select Sector

$23.16

-0.24 (-1.03%)

SPY

SPDR S&P 500 ETF Trust

$234.59

-0.75 (-0.32%)

DIA

Diamonds Fund ETF

$205.25

-0.26 (-0.13%)

IWM

iShares Trust Russell 2000 Index Fund

$137.21

-0.31 (-0.23%)

XLV

Health Care Select Sector SPDR

$73.68

-0.44 (-0.59%)

XLE

Energy Select Sector SPDR

$67.79

-0.34 (-0.50%)

XLK

Technology Select Sector SPDR

$53.17

-0.11 (-0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PGNX

Progenics

$7.75

-0.38 (-4.67%)

09:08
04/24/17
04/24
09:08
04/24/17
09:08
Recommendations
Progenics analyst commentary  »

Needham remains a buyer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

ADMS

Adamas Pharmaceuticals

$15.57

-0.05 (-0.32%)

09:08
04/24/17
04/24
09:08
04/24/17
09:08
Hot Stocks
Adamas: ADS-5012 data confirms reduction in levodopa-induced dyskinesia »

Adamas Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

  • 24

    Aug

AMZN

Amazon.com

$898.53

-3.53 (-0.39%)

09:07
04/24/17
04/24
09:07
04/24/17
09:07
Hot Stocks
Amazon launches self-service marketplace for subscription providers »

Amazon.com announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 27

    Apr

  • 16

    May

  • 23

    May

HRS

Harris

$110.27

0.32 (0.29%)

09:06
04/24/17
04/24
09:06
04/24/17
09:06
Hot Stocks
Harris awarded 5-year, $875M ceiling multi-award IDIQ contract by USAF »

Harris has been awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

HEI

Heico

$69.54

0.7 (1.02%)

09:06
04/24/17
04/24
09:06
04/24/17
09:06
Hot Stocks
Heico announces 25% increase in credit facility »

HEICO Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VECO

Veeco

$31.00

0.6 (1.97%)

, UTEK

Ultratech

$30.01

0.13 (0.44%)

09:06
04/24/17
04/24
09:06
04/24/17
09:06
Recommendations
Veeco, Ultratech analyst commentary  »

Veeco price target raised…

VECO

Veeco

$31.00

0.6 (1.97%)

UTEK

Ultratech

$30.01

0.13 (0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

BBOX

Black Box

$9.95

-0.25 (-2.45%)

, FSTR

L.B. Foster

$13.40

-0.15 (-1.11%)

09:05
04/24/17
04/24
09:05
04/24/17
09:05
Hot Stocks
Black Box names David Russo as SVP, CFO, Treasurer »

Black Box Corporation…

BBOX

Black Box

$9.95

-0.25 (-2.45%)

FSTR

L.B. Foster

$13.40

-0.15 (-1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 09

    May

CDW

CDW

$57.76

-0.42 (-0.72%)

09:05
04/24/17
04/24
09:05
04/24/17
09:05
Initiation
CDW initiated  »

CDW initiated with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

RILY

B. Riley Financial

$14.75

-0.05 (-0.34%)

09:04
04/24/17
04/24
09:04
04/24/17
09:04
Hot Stocks
B. Riley Financial acquires rights to manage Dialectic hedge funds »

B. Riley Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.